Steve Jackson

Steve is the Originator of Olaparib/Lynparza, recently partnered by AstraZeneca with Merck and valued as an asset at up to $17BN, and used to treat 30,000 patients worldwide to date.

Steve is the University of Cambridge Frederick James Quick and Cancer Research UK Professor of Biology. He is also Head of Cancer Research UK Laboratories at the Wellcome Trust/Cancer Research UK Gurdon Institute. He is a leading expert in the field of DNA repair and DNA-damage signalling and invented Lynparza, the world’s first marketed DNA-repair enzyme inhibitor, an effective treatment of breast and other cancers.

Steve’s awards include the Heineken Prize for Science by the Royal Netherlands Academy of Arts and Science in 2016 and the UK GSN Medal for his contributions to the field of genome stability. He is a fellow of the Royal Society.